Bevacizumab

Regimen

• Bevacizumab (Avastin) 10 mg/kg iv q2w

References

Yang, JC et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349:427